Idiopathic Anaphylaxis - What to do when a cause eludes you
Price: FREE for members and non-members
Session recorded on February 18, 2020
Speaker: Anne Ellis, MD
Viewers can earn credit by completing the post test questions.
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
There is no commercial support for this activity.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of this video recording, participant should be able to:
1. Describe the essential pathophysiologic mechanisms of anaphylaxis
2. Diagnose idiopathic anaphylaxis accurately
3. Discuss appropriate work up strategies for anaphylaxis when cause is not obvious
All identified conflicts of interest have been resolved.
Michael Blaiss, MD, Planner
Disclosures: Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Anne Ellis, MD, Speaker
Disclosures: Grants to Institution: Bayer LLC, Circassia Ltd., Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Marck, Novartis, Pfizer, Regeneron and Sanofi, Advisory Boards: ALK Abello, AstraZeneca, Aralez, Bausch Health, Circassia Ltd., GlaxoSmithKline, Johnson & Johnson, Merck, Mylan, Novartis, Pediapharm and Pfizer
Speaker: ALK, Aralez, AstraZeneca, Boerhinger-Ingelheim, CACME, Meda, Mylan, Merck, Novartis, Pediapharm, Pfizer, The ACADMEY, and Takeda
Other: Independent consultant to Allergy Therapeutics, Bayer LLC, Ora Inc. and Regeneron in the past.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance